Land: Canada
Sprog: engelsk
Kilde: Health Canada
ESCITALOPRAM (ESCITALOPRAM OXALATE)
MINT PHARMACEUTICALS INC
N06AB10
ESCITALOPRAM
20MG
TABLET
ESCITALOPRAM (ESCITALOPRAM OXALATE) 20MG
ORAL
100
Prescription
SELECTIVE-SEROTONIN REUPTAKE INHIBITORS
Active ingredient group (AIG) number: 0150435004; AHFS:
APPROVED
2015-01-16
MINT-ESCITALOPRAM (escitalopram oxalate) Product Monograph Page 1 of 60 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATIO N PR MINT-ESCITALOPRAM escitalopram oxalate (as escitalopram) Tablets, 10, 15, 20 mg escitalopram (base), Oral Antidepressant / Anxiolytic / Antiobsessional Mint Pharmaceuticals Inc. 6575 Davand Drive Mississauga, Ontario L5T 2M3 Date of Initial Authorization: Jan 16, 2015 Date of Revision: MAR 15, 2024 Submission Control Number: 280949 MINT-ESCITALOPRAM (escitalopram oxalate) Product Monograph Page 2 of 60 RECENT MAJOR LABEL CHANGES 3 SERIOUS WARNINGS AND PRECAUTIONS BOX 05/2024 1 INDICATIONS 08/2022 1 INDICATIONS, 1.2 Geriatrics 08/2022 4 DOSAGE AND ADMINISTRATION, 4.1 Dosing Considerations 08/2022 4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and Dosage Adjustment 08/2022 7 WARNINGS AND PRECAUTIONS, Hematologic 08/2022 7 WARNINGS AND PRECAUTIONS, Reproductive Health: Female and Male Potential 08/2022 7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant Women 08/2022 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES ........................................................................................................ 2 TABLE OF CONTENTS .......................................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................................................. 4 1 INDICATIONS ........................................................................................................................... 4 1.1 Pediatrics ............................................................................................................................ 4 1.2 Geriatrics ............................................................................................................................ 4 2 CONTRAINDICATIONS ..................................................................................... Læs hele dokumentet